Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Strainsforpains
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Strainsforpains CEO Discusses Entering $191 Bn Anti-Inflammatory Market with GenBio
Details : Under the agreement, GenBio will license potentially new, next generation of anti-inflammatory cannabinoids to be included in Strainsforpains CBD branded products.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
March 14, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Strainsforpains
Deal Size : Undisclosed
Deal Type : Licensing Agreement